Difference between revisions of "Talk:Programmed death-ligand 1"

From Libre Pathology
Jump to navigation Jump to search
(Created page with "Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal | last1 = Rosenberg | first1 = JE. | last2 = Hoffman-Censits | first2 = J. | last3 = Powles | first3...")
 
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Urothelial carcinoma==
Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal  | last1 = Rosenberg | first1 = JE. | last2 = Hoffman-Censits | first2 = J. | last3 = Powles | first3 = T. | last4 = van der Heijden | first4 = MS. | last5 = Balar | first5 = AV. | last6 = Necchi | first6 = A. | last7 = Dawson | first7 = N. | last8 = O'Donnell | first8 = PH. | last9 = Balmanoukian | first9 = A. | title = Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. | journal = Lancet | volume = 387 | issue = 10031 | pages = 1909-20 | month = May | year = 2016 | doi = 10.1016/S0140-6736(16)00561-4 | PMID = 26952546 }}</ref>
Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal  | last1 = Rosenberg | first1 = JE. | last2 = Hoffman-Censits | first2 = J. | last3 = Powles | first3 = T. | last4 = van der Heijden | first4 = MS. | last5 = Balar | first5 = AV. | last6 = Necchi | first6 = A. | last7 = Dawson | first7 = N. | last8 = O'Donnell | first8 = PH. | last9 = Balmanoukian | first9 = A. | title = Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. | journal = Lancet | volume = 387 | issue = 10031 | pages = 1909-20 | month = May | year = 2016 | doi = 10.1016/S0140-6736(16)00561-4 | PMID = 26952546 }}</ref>
==Renal cell carcinoma==
*2015 paper: ~ 15% respond to PD-L1[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647139/]
**Biomarkers predict response
*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]
*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]
*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922]
==CPS and TPS==
CPS in lymph nodes:
*H&N: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/
*H&N cytology: https://pmc.ncbi.nlm.nih.gov/articles/PMC8810615/
*Breast: https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z
==References==
{{Reflist|1}}

Latest revision as of 15:26, 29 October 2024

Urothelial carcinoma

Urothelial carcinoma - atezolizumab[1]

Renal cell carcinoma

  • 2015 paper: ~ 15% respond to PD-L1[1]
    • Biomarkers predict response
  • 2018 paper: ~ 70% durable response among those that discontinue d/t side effects[2]
  • 2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[3]
  • 2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[4]

CPS and TPS

CPS in lymph nodes:

References

  1. ↑ Rosenberg, JE.; Hoffman-Censits, J.; Powles, T.; van der Heijden, MS.; Balar, AV.; Necchi, A.; Dawson, N.; O'Donnell, PH. et al. (May 2016). "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.". Lancet 387 (10031): 1909-20. doi:10.1016/S0140-6736(16)00561-4. PMID 26952546.
Retrieved from "https://librepathology.org/w/index.php?title=Talk:Programmed_death-ligand_1&oldid=53292"